Primary objective: To evaluate the efficacy in terms of oocyte retrieval number of rLH supplement in women with hyporesponse to rFSH after pituitary downregulation. Secondary objective: To further explore the efficacy of rLH supplement in women with hyporesponse to rFSH after pituitary downregulation To evaluate the safety of rLH supplementation in hyporesponse women
Primary endpoint: Number of oocyte retrieved Secondary endpoints: 1. Oestrodial on hCG day (pg/ml) 2. Number of embryos 3. Implantation rate (%) 4. Clinical pregnancy rate (%) 5. Ongoing PR per IVF cycle (%) 6. Abortion rate (%) 7. Ampoules of rFSH 8. FertiQoL score Safety endpoint: adverse events
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
150
Luveris 75IU or 150IU depending on the patient conditions, subcutaneous injection, Qd, from Day 8 till hCG Day
Peking University third Hospital
Beijing, Beijing Municipality, China
Number of oocyte retrieved
Time frame: 2009Dec-2010Oct
1. Oestrodial on hCG day (pg/ml) Safety: adverse events
Time frame: 2009 Dec-2010 Oct
2. Number of embryos
Time frame: 2009 Dec-2010 Oct
3. Implantation rate (%)
Time frame: 2009 Dec-2010 Oct
4. Clinical pregnancy rate (%)
Time frame: 2009 Dec-2010 Oct
5. Ongoing PR per IVF cycle (%)
Time frame: 2009 Dec-2010 Oct
6. Abortion rate (%)
Time frame: 2009 Dec-2010 Oct
7. Ampoules of rFSH
Time frame: 2009 Dec-2010 Oct
8. FertiQoL score Safety: adverse events
Time frame: 2009 Dec-2010 Oct
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.